ArticleThe Journal of clinical investigation2012
Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation.
Article in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 47 citations in OpenAlex.
- Replication-competent SIVcpz CRISPR screen identifies barriers to successful cross-species transmission.Journal of virology · 2026Article
- Decoding HIV-1 Next Move Through Matrix Protein p17 Quasi-Species.MicrobiologyOpen · 2026Article
- Evasion of CARD8 activation during HIV-1 assembly.Science advances · 2025Article
- Viral evolution of SIV chimpanzee toward HIV-1 using humanized mice.Journal of medical primatology · 2023Article
- Article
- Article
- Evolutionary plasticity of SH3 domain binding by Nef proteins of the HIV-1/SIVcpz lentiviral lineage.PLoS pathogens · 2021Article
- Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Cell Type-Dependent Escape of Capsid Inhibitors by Simian Immunodeficiency Virus SIVcpz.Journal of virology · 2020Article
- A role for gorilla APOBEC3G in shaping lentivirus evolution including transmission to humans.PLoS pathogens · 2020Article
- Article
- HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4Journal of virology · 2020Article
- Cross-Species Transmission and Evolution of SIV Chimpanzee Progenitor Viruses Toward HIV-1 in Humanized Mice.Frontiers in microbiology · 2020Article
- Onward transmission of viruses: how do viruses emerge to cause epidemics after spillover?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019Review
- IFI16 Targets the Transcription Factor Sp1 to Suppress HIV-1 Transcription and Latency Reactivation.Cell host & microbe · 2019Article
- A glycan shield on chimpanzee CD4 protects against infection by primate lentiviruses (HIV/SIV).Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- How host genetics dictates successful viral zoonosis.PLoS biology · 2019Article
- CD4 receptor diversity in chimpanzees protects against SIV infection.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Parallel molecular evolution and adaptation in viruses.Current opinion in virology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
SIVs infecting wild-living apes in west central Africa have crossed the species barrier to humans on at least four different occasions, one of which spawned the AIDS pandemic. Although the chimpanzee precursor of pandemic HIV-1 strains must have been able to infect humans, the capacity of SIVcpz strains to replicate in human lymphoid tissues (HLTs) is not known. Here, we show that SIVcpz strains from two chimpanzee subspecies are capable of replicating in human tonsillary explant cultures, albeit only at low titers. However, SIVcpz replication in HLT was significantly improved after introduction of a previously identified human-specific adaptation at position 30 in the viral Gag matrix protein. An Arg or Lys at this position significantly increased SIVcpz replication in HLT, while the same mutation reduced viral replication in chimpanzee-derived CD4(+) T cells. Thus, naturally occurring SIVcpz strains are capable of infecting HLTs, the major site of HIV-1 replication in vivo. However, efficient replication requires the acquisition of a host-specific adaptation in the viral matrix protein. These results identify Gag matrix as a major determinant of SIVcpz replication fitness in humans and suggest a critical role in the emergence of HIV/AIDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.